Utility of a PI3K/mTOR Inhibitor (NVP-BEZ235) for Thyroid Cancer Therapy

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Lin, Shu Fu ^a   Huang, Yu Yao ^a   Lin, Jen Der ^a   Chou, Ting Chao ^b   Hsueh, Chuen ^a   Wong, Richard J ^b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IRINOTECAN; LACTATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PACLITAXEL; PROTEIN P27; PROTEIN S6;

ANAPLASTIC CARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; ENZYME INHIBITORS; FLOW CYTOMETRY; HUMANS; IMIDAZOLES; MICE; PHOSPHATIDYLINOSITOL 3-KINASES; QUINOLINES; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TOR SERINE-THREONINE KINASES;

EID: 84867529962     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046726     Document Type: Article

References (48)

1. Davies L, Welch HG, (2006) Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295: 2164-2167.
2. Chen AY, Jemal A, Ward EM, (2009) Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 115: 3801-3807.
3. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, et al. (2009) Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 69: 4885-4893.
4. Nikiforov YE, Nikiforova MN, (2011) Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 7: 569-580.
5. Sippel RS, Kunnimalaiyaan M, Chen H, (2008) Current management of medullary thyroid cancer. Oncologist 13: 539-547.
6. Engelman JA, (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9: 550-562.
7. Faivre S, Kroemer G, Raymond E, (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5: 671-688.
8. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB, (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4: 988-1004.
9. Wu G, Mambo E, Guo Z, Hu S, Huang X, et al. (2005) Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab 90: 4688-4693.
10. Hou P, Liu D, Shan Y, Hu S, Studeman K, et al. (2007) Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cance. Clin Cancer Res 13: 1161-1170.
11. Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI, (2008) Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab 93: 278-284.
12. Liu Z, Hou P, Ji M, Guan H, Studeman K, et al. (2008) Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 93: 3106-3116.
13. Abubaker J, Jehan Z, Bavi P, Sultana M, Al-Harbi S, et al. (2008) Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. J Clin Endocrinol Metab 93: 611-618.
14. Wang Y, Hou P, Yu H, Wang W, Ji M, et al. (2007) High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. J Clin Endocrinol Metab 92: 2387-2390.
15. Carlomagno F, Santoro M, (2011) Thyroid cancer in 2010: a roadmap for targeted therapies. Nat Rev Endocrinol 7: 65-67.
16. Rapa I, Saggiorato E, Giachino D, Palestini N, Orlandi F, et al. (2011) Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma. J Clin Endocrinol Metab 96: 2146-2153.
17. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, et al. (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7: 1851-1863.
18. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, et al. (2008) NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68: 8022-8030.
19. Marone R, Erhart D, Mertz AC, Bohnacker T, Schnell C, et al. (2009) Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors. Mol Cancer Res 7: 601-613.
20. Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, et al. (2010) NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res 16: 530-540.
21. Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, et al. (2010) Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res 16: 5424-5435.
22. Santiskulvong C, Konecny GE, Fekete M, Chen KY, Karam A, et al. (2011) Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clin Cancer Res 17: 2373-2384.
23. Ohta K, Pang XP, Berg L, Hershman JM, (1997) Growth inhibition of new human thyroid carcinoma cell lines by activation of adenylate cyclase through the beta-adrenergic receptor. J Clin Endocrinol Metab 82: 2633-2638.
24. Huang YY, Yu Z, Lin SF, Li S, Fong Y, et al. (2007) Nectin-1 is a marker of thyroid cancer sensitivity to herpes oncolytic therapy. J Clin Endocrinol Metab 92: 1965-1970.
25. Lin SF, Yu Z, Riedl C, Woo Y, Zhang Q, et al. (2007) Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus. Surgery 142: 976-983 discussion 976-983.
26. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, et al. (2008) Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 93: 4331-4341.
27. Chou TC, Martin N (2005) CompuSyn for Drug Combinations: PC Software and User's Guide: A Computer Program for Quantitation of Synergism and Antagonism in Drug Combinations, and the Determination of IC50 and ED50 and LD50 Values. Paramus: ComboSyn.
28. Chou TC, Talalay P, (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
29. Chou TC, (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681.
30. Chou TC, (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70: 440-446.
31. Lapenna S, Giordano A, (2009) Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8: 547-566.
32. Hughes AN, Griffin MJ, Newell DR, Calvert AH, Johnston A, et al. (2000) Clinical pharmacokinetic and in vitro combination studies of nolatrexeddihydrochloride (AG337, Thymitaq) and paclitaxel. Br J Cancer 82: 1519-1527.
33. Rothenberg ML, Kuhn JG, Schaaf LJ, Rodriguez GI, Eckhardt SG, et al. (2001) Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. Ann Oncol 12: 1631-1641.
34. Sprinz E, Caldas AP, Mans DR, Cancela A, DiLeone L, et al. (2001) Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index. Am J Clin Oncol 24: 177-184.
35. Foster KG, Fingar DC, (2010) Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem 285: 14071-14077.
36. Iwenofu OH, Lackman RD, Staddon AP, Goodwin DG, Haupt HM, et al. (2008) Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy. Mod Pathol 21: 231-237.
37. Motti ML, Califano D, Troncone G, De Marco C, Migliaccio I, et al. (2005) Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization. Am J Pathol 166: 737-749.
38. Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, et al. (2005) Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 65: 10992-11000.
39. Kim SH, Juhnn YS, Song YS, (2007) Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells. Ann N Y Acad Sci 1095: 82-89.
40. Shafer A, Zhou C, Gehrig PA, Boggess JF, Bae-Jump VL, (2010) Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis. Int J Cancer 126: 1144-1154.
41. Ain KB, Egorin MJ, DeSimone PA, (2000) Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 10: 587-594.
42. Fekete M, Santiskulvong C, Eng C, Dorigo O, (2012) Effect of PI3K/Akt pathway inhibition-mediated G1 arrest on chemosensitization in ovarian cancer cells. Anticancer Res 32: 445-452.
43. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J, (2002) Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 16: 1472-1487.
44. Liu Z, Wu G, Xing M, (2009) Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res 69: 7311-7319.
45. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, et al. (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118: 3065-3074.
46. Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW, (2011) Synergistic action of a RAF inhibitor and a dual PI-3 Kinase/mTOR inhibitor in thyroid cancer. Clin Cancer Res 17: 6482-6489.
47. Liu D, Xing J, Trink B, Xing M, (2010) BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus. Int J Cancer 127: 2965-2973.
48. Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW, (2009) Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab 94: 4107-4112.